STOCK TITAN

Personalis to Announce First Quarter 2024 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Personalis, Inc. (PSNL) will announce its first quarter 2024 financial results on May 8, 2024. The company, a leader in advanced genomics for cancer, will host a conference call and webcast to discuss the results and recent highlights.
Personalis, Inc. (PSNL) annuncerà i suoi risultati finanziari del primo trimestre del 2024 il 8 maggio 2024. La compagnia, leader nell'avanzata genomica per il cancro, organizzerà una conferenza telefonica e un webcast per discutere i risultati e gli ultimi sviluppi.
Personalis, Inc. (PSNL) anunciará sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024. La empresa, líder en genómica avanzada para el cáncer, realizará una llamada de conferencia y un webcast para discutir los resultados y los recientes logros.
Personalis, Inc. (PSNL)는 2024년 첫 분기 재무 결과를 2024년 5월 8일에 발표할 예정입니다. 암 관련 선진 유전체학 분야의 선도 기업인 이 회사는 결과와 최근 하이라이트를 논의하기 위해 컨퍼런스 콜과 웹캐스트를 개최할 것입니다.
Personalis, Inc. (PSNL) annoncera ses résultats financiers pour le premier trimestre de 2024 le 8 mai 2024. L'entreprise, leader en génomique avancée pour le cancer, organisera une conférence téléphonique et un webcast pour discuter des résultats et des points saillants récents.
Personalis, Inc. (PSNL) wird seine Finanzergebnisse für das erste Quartal 2024 am 8. Mai 2024 bekannt geben. Das Unternehmen, ein führender Anbieter in der fortschrittlichen Genomik für Krebs, wird eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse und aktuelle Höhepunkte zu besprechen.
Positive
  • None.
Negative
  • None.

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the call by dialing 844-826-3035 for domestic callers or 412-317-5195 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Investors:

Caroline Corner

investors@personalis.com

415-202-5678

Media:

pr@personalis.com

Source: Personalis, Inc.

FAQ

When will Personalis, Inc. (PSNL) announce its first quarter 2024 financial results?

Personalis, Inc. (PSNL) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024.

What is Personalis, Inc.'s (PSNL) focus area?

Personalis, Inc. (PSNL) is a leader in advanced genomics for cancer.

How can interested parties access Personalis, Inc.'s (PSNL) conference call and webcast?

Interested parties can access the call by dialing 844-826-3035 for domestic callers or 412-317-5195 for international callers. The webinar can be accessed on the company's website at investors.personalis.com.

Personalis, Inc.

NASDAQ:PSNL

PSNL Rankings

PSNL Latest News

PSNL Stock Data

474.58M
54.05M
19.3%
53.16%
4.04%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FREMONT